- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07657234
tDCS for Late-Life Depression
High-Dose Spaced Bilateral tDCS for Late-Life Depression: Open-Label Pilot Study
The purpose of this research study is to determine the effectiveness of Transcranial direct current stimulation (tDCS) therapy in the treatment of participants with Late-life depression (LLD).
The study will evaluate feasibility, safety, and tolerability of high-dose (6mA) bilateral tDCS delivered as three daily sessions, 3 times a week, for 3 weeks in older adults (60 y/o and older) with late-life depression.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Clinical Research Coordinator
- Numéro de téléphone: 214-645-2991
- E-mail: alexus.washington@utsouthwestern.edu
Lieux d'étude
-
-
Texas
-
Dallas, Texas, États-Unis, 75390
- University of Texas Southwestern Medical Center
-
Chercheur principal:
- Andre Russowsky Brunoni, MD PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
Participants must meet all of the following criteria:
- age 60 years or older;
- diagnosis of unipolar major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by the Mini International Neuropsychiatric Interview (MINI);
- score of 17 or higher on the 17-item Hamilton Depression Rating Scale (HDRS-17) at screening;
- stable antidepressant regimen for at least four weeks prior to enrollment, if applicable;
- capacity to provide informed consent;
- Clinical Dementia Rating scale of 0 or 0.5.
Exclusion Criteria:
Participants meeting any of the following criteria will be excluded:
- contraindications to tDCS including metallic cranial implants, skin conditions at electrode sites (eczema, open wounds, burns, lesions), or history of adverse reaction to tDCS;
- contraindications to magnetic resonance imaging (MRI) including pacemaker, cochlear implants, ferromagnetic implants, or claustrophobia;
- history of seizures or epilepsy;
- bipolar disorder, psychotic disorders, or severe personality disorder;
- dementia or MoCA score below 17;
- substance use disorder within the past six months;
- neuromodulation treatment including electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), tDCS, or vagus nerve stimulation (VNS) within the past six months;
- active suicidal ideation with plan or intent requiring a higher level of care;
- concurrent use of medications that substantially lower seizure threshold;
- pregnancy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: tDCS in older adults with LLD
|
High-intensity (6 mA), spaced (three daily sessions, 3 times a week, for 3 weeks) transcranial direct current stimulation (tDCS) in older adults (60 y/o and over) with Late-Life Depression
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Completion Rate
Délai: 6 weeks
|
The proportion of enrolled participants who complete at least 7 of 9 treatment days.
|
6 weeks
|
|
Target dose achievement
Délai: 6 weeks
|
The proportion of participants who reach their calculated target dose without dose-limiting intolerance.
|
6 weeks
|
|
Session completion
Délai: 6 weeks
|
The proportion of scheduled sessions completed across all participants.
|
6 weeks
|
|
Adverse event profile
Délai: 6 weeks
|
Including incidence, severity, and time course of adverse events.
|
6 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Target engagement
Délai: 6 weeks
|
Resting-state fMRI measures functional connectivity between the DLPFC and subgenual anterior cingulate cortex (sgACC). The DLPFC-sgACC connectivity is a biomarker of depression that predicts treatment response to neuromodulation. Target engagement would be a significant change in DLPFC-sgACC connectivity. |
6 weeks
|
|
Clinical - HDRS-17
Délai: 6 weeks
|
Clinical outcomes are assessed using the HDRS-17 at baseline, weeks 1-5, and week 6.
Response is defined as ≥50% reduction in HDRS-17 from baseline.
Remission is defined as HDRS-17 ≤7.
|
6 weeks
|
|
Correlation of Stimulation Dose With Change in HDRS 17 Scores
Délai: 6 weeks
|
Exploratory dose-response analyses will examine correlations between the device stimulation and the changes in clinical outcomes (HDRS-17). This is assessed by correlating achieved baseline E-field (Structural MRI (T1- and T2-weighted) values) and changes in clinical outcomes measured by Hamilton Depression Rating Scale-17 item (HDRS-17). Change in HDRS 17 is defined as the difference between baseline and post-treatment scores at 6 weeks. Correlation analyses (Pearson or Spearman coefficients) are used to quantify the relationship. |
6 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Andre Russowsky Brunoni, MD PhD, University of Texas Southwestern Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STU20260143
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .